Faculty of Medical Science and Research, Department of Pharmacy, Sai Nath University, Ranchi, Jharkhand 835219, India
Human Metapneumovirus (hMPV) has become a major respiratory pathogen since 2001 and is a challenge in clinical practice and public health. This review covers the molecular architecture, pathogenesis and clinical features of hMPV in different patient populations. The virus has remarkable genetic diversity with two main lineages (A and B) and multiple sublineages which affects its adaptability and immune evasion. Pathogenesis involves complex molecular interactions between viral surface proteins and host cell receptors which trigger complex inflammatory responses that lead to respiratory symptoms. Epidemiology shows different seasonal patterns with peak in late winter and early spring in temperate climate.The virus shows toxicity in a vulnerable population, including small children, elderly persons and immunalvanized patients, where it can cause severe infection of the lower respiratory tract. Clinical manifestations range from mild upper respiratory symptoms to serious complications such as bronchiolitis and pneumonia, with special ideas requiring a high-risk population. Current clinical approaches mainly depend on the molecular methods, especially the RT-PCR, while imaging studies provide important information about the seriousness and progress of the disease. Therapeutic landscape remains largely helpful, exposing the urgent need for specific antiviral interventions. Research directions focus on the development of targeted treatments, vaccines and better clinical instruments, resolving the challenges of viral development and resistance. This article emphasizes the important importance of understanding host-controactive interactions, immune reactions and viral genetics in developing effective interventions. The future perspective highlights the need for advanced monitoring systems, cross-disciplinary cooperation and new therapeutic strategies. Integration of Artificial Intelligence and machine learning technologies can accelerate research progress in many areas from vaccine design to clinical accuracy. This extensive analysis underlines constant challenges and opportunities in HMPV research, emphasizing the importance of constant scientific investigation and public health preparations in addressing this important respiratory pathogen. The virus shows toxicity in a vulnerable population, including small children, elderly persons and immunocompromised patients, where it can cause severe infection of the lower respiratory tract. Clinical manifestations range from mild upper respiratory symptoms to serious complications such as bronchiolitis and pneumonia, with special ideas requiring a high-risk population. Current clinical approaches mainly depend on the molecular methods, especially the RT-PCR, while imaging studies provide important information about the seriousness and progress of the disease.Therapeutic landscape remains largely helpful, exposing the urgent need for specific antiviral interventions. Research directions focus on the development of targeted treatments, vaccines and better clinical instruments, resolving the challenges of viral development and resistance. This article emphasizes the important importance of understanding host-controactive interactions, immune reactions and viral genetics in developing effective interventions. The future perspective highlights the need for advanced monitoring systems, cross-disciplinary cooperation and new therapeutic strategies. Integration of Artificial Intelligence and machine learning technologies can accelerate research progress in many areas from vaccine design to clinical accuracy. This extensive analysis underlines constant challenges and opportunities in HMPV research, emphasizing the importance of constant scientific investigation and public health preparations in addressing this important respiratory pathogen
Human metapneumovirus (hMPV) has emerged as a fascinating and significant player in the landscape of respiratory infections since its groundbreaking discovery by Dutch researchers in 2001. This revelation marked a turning point in our understanding of viral respiratory illnesses, as scientists realized they had uncovered a previously unknown pathogen that had likely been circulating in human populations for decades, if not centuries. The virus belongs to the diverse Paramyxoviridae family, sharing remarkable genetic and structural similarities with its molecular cousin, respiratory syncytial virus (RSV), though possessing unique characteristics that set it apart in both behaviour and impact. The virus's ability to infect human respiratory cells demonstrates an intricate molecular dance, where viral surface proteins expertly recognize and bind to specific receptors on human airway cells, initiating a cascade of events that leads to infection. This process becomes particularly efficient in certain vulnerable populations, creating a perfect storm of susceptibility. Young children, whose immune systems are still developing their defensive repertoire, often experience more severe manifestations of hMPV infection. Similarly, elderly adults, dealing with the natural decline in immune function that accompanies aging, and individuals with compromised immune systems due to various medical conditions or treatments, face heightened risks from this viral invader [1-3]. What makes hMPV particularly challenging from a clinical perspective is its remarkable ability to mimic other respiratory infections. The virus orchestrates a symphony of symptoms that can include coughing, wheezing, nasal congestion, and fever – a presentation that closely mirrors other common respiratory pathogens. This similarity has historically led to significant underdiagnosis, as healthcare providers, working with limited diagnostic tools, often attributed these symptoms to more commonly recognized viral culprits. The challenge of accurate diagnosis has been further compounded by traditional laboratory testing limitations, where older diagnostic methods lacked the sensitivity and specificity needed to definitively identify hMPV. The global impact of hMPV extends far beyond individual cases, creating ripple effects through healthcare systems and communities worldwide. Epidemiological studies have revealed fascinating patterns of viral circulation, with seasonal peaks typically occurring during late winter and early spring in temperate climates. This timing often overlaps with other respiratory virus seasons, creating complex patterns of viral co-circulation that challenge both clinical management and public health responses. The virus demonstrates remarkable genetic diversity, with at least two major genetic lineages identified, each containing multiple subgroups. This diversity not only complicates vaccine development efforts but also influences the virus's ability to evade immune responses and potentially cause reinfections throughout life. Recent advances in molecular diagnostics, particularly the development of sensitive PCR-based testing methods, have begun to illuminate the true burden of hMPV infections. These technological improvements have revealed that the virus is responsible for a significant proportion of respiratory infections previously classified as "unknown origin," highlighting its underappreciated role in global respiratory disease burden [4, 5].
Human Metapnumovirus (hMPV) is an attractive respiratory pathogen that has attracted significant attention to the medical research community since its initial discovery in the Netherlands in 2001. Pnumoviride family member and particularly related to the Metapnumovirus genus, this virus displays remarkable structural and functional features affecting its behavior in human host. At its core, hMPV takes a negative-sense, single-stranded RNA genome, stretching up to about 13,000 base papers, and serves as blueprint for viral replication and protein synthesis. The molecular structure of HMPV is particularly interesting, which includes eight specific proteins that work together to convenient viral infections and spread. Nucleoprotein (N) plays a significant role in the safety of the viral genome, while phosphoprotein (P) serves as an essential cooperator for viral replica. Matrix protein (M) provides structural support and helps arrange viral components during the assembly. Fusion protein (F) enables the virus to merge with host cell membrane, which is an important step in the infection process. Matrix Protein-2 (M2) contributes to the regulation of viral assembly and RNA synthesis, while small hydrophobic protein (SH) may affect the reactions of host cell. Glycoprotein (G) facilitates viruses in connecting to host cells, and large polymerase protein (L) conducts replication (replication) of the viral genome. Through extensive genetic analysis and epidemic studies, researchers have identified specific developmental types in the population of hMPV (Human Metaponumovirus), which has identified two major genetic descendants, called A and B. These early descendants are further divided into sub-divisions (A1, A2, B1, and B2), each of whom has distinct genetic properties and potential different clinical expressions. This genetic diversity not only shows the virus’ adaptation and development ability, but also presents significant effects for vaccine development and therapeutic strategies. Understanding these variations becomes important for healthcare providers and researchers who are trying to effectively deal with hMPV infections and develop targeted treatments for various viral strains [6, 7].
Dr. K. Rajeswar Dutt, Mahesh Kumar Yadav, Ankita Singh, Indrajeet Kumar Mahto, Sudarshan Rawani, Gangadhar Singh, Suraj Kumar, Shivam Kashyap, Jinten Goray, Priyanshu Kumar Singh1, Arnab Roy*, The Hidden Menace: Human Metapneumovirus Infection (hMPV): A Review of Clinical Manifestations, Diagnosis, And Management Strategies, Int. J. Sci. R. Tech., 2025, 2 (2), 215-231. https://doi.org/10.5281/zenodo.14940353
10.5281/zenodo.14940353
